How did Recursion's revenue and expenses trend in Q4 2024 compared to previous quarters?

Recursion Pharmaceuticals Inc. (RXRX) demonstrated an upward trend in revenue and an increase in expenses from Q1 to Q4 2024, with the most significant growth occurring in the third quarter of 2024. 1. **Revenue Trend**: - Q1 2024: $13.79 million - Q2 2024: $28.21 million, indicating a 104% increase from Q1. - Q3 2024: $54.29 million, representing a 93% increase from Q2. - Q4 2024: $58.84 million, showing a 8% increase from Q3. 2. **Expense Trend**: - Data for expenses is not provided for Q1, Q2, and Q3 2024, only for Q4 2024. - Q4 2024: The total expenses for the period ending Q4 2024 are not available, which makes it difficult to analyze the trend of expenses over the previous quarters. The revenue trend indicates a substantial increase in the third quarter of 2024, with a more modest increase in the fourth quarter. The lack of expense data for the first three quarters makes it impossible to analyze the expense trend over the same period. However, the significant revenue increase from Q3 to Q4 suggests that any increase in expenses would have been offset by higher revenue, potentially leading to improved financial performance in Q4 2024 compared to previous quarters.